)
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
The industry, on its part, is drafting out the road map for vaccination and where they can chip in.
AstraZeneca vaccine is likely to cost Rs 500-600 per dose in the private market
The firm said subject was now safe. Though it was reported to the drug regulator within 24 hours, the event turned out to be unrelated to the vaccine.
In September, DRL and RDIF had tied up to conduct clinical trials and distribute the vaccine in India.
Pfizer and BioNTech said they plan to submit the data to other regulatory agencies around the world.
Players like Indian Immunologicals willing to partner US firm to manufacture here
Its vaccine's temperature requirements give it an edge over Pfizer's for distribution in India
As India prepares a road map for a Covid-19 vaccination drive next year, the lack of cold chain infrastructure is a key bottleneck
Delhi reels under a strong second wave of infections with daily tally of over 8,000 cases, Mumbai seems to be breathing easy with almost one-eighth that number
Pune company recruits over 1,600 participants in India for phase 3 trials of Covishield.
The funds for research have been allocated to the Department of Biotechnology as part of the stimulus package announced by the finance minister
For Siemens, around 50 per cent are first-time buyers, 30 per cent are adding machines for Covid-19
Fosun-owned Gland Pharma sets price band for its IPO at Rs 1,490-1,500 per share
Revenues remain flat, sequential improvement in India and US revenues
Our focus right now is to complete the transaction and the integration, said Pai
The deal may mark the exit of US based hospital chain from India
Emergency use authorisation to continue; recently, WHO had raised doubts about efficacy of drug in treatment of Covid-19 patients
While the country already has a huge cold chain set-up, it may not be enough for vaccine delivery
Europe is now suffering from a second wave of the Sars-CoV-2 virus attack
Industry says revised PLI scheme will attract more MSMEs to invest as minimum investment clause done away with